It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...

Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.

Larger trials with longer follow-up are still needed to cement CSP as an alternative to biventricular pacing, experts say.

The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.

Without reducing death or major bleeding, Toby Rogers says the results can be interpreted based on one’s ‘starting ...

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...

This month, readers gravitated most toward the memory of David Taggart. Stories interpreting data from ESC 2026 also drew ...

The safety results of ACASA-TAVI and NOTION-4 were discordant as well, Windecker said. “But please note that overall event numbers were very low, the treatment estimates are imprecise, and the ...

The lack of impact on outcomes was surprising, says the investigator, though the FAST-CTCA trial may still come through.

An intervention in rural China continued to impact hypertension, CV events, and dementia risk 4 years after it ended.

As the first trial of these valve interventions to impact HF hospitalization and mortality, it “feels like a COAPT-like ...